𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Method for Defining Binding Sites Involved in Protein–Protein Interactions: Analysis of the Binding of Plasminogen Activator Inhibitor 1 to the Somatomedin Domain of Vitronectin

✍ Scribed by Gordon Royle; Gary Deng; Dietmar Seiffert; David J. Loskutoff


Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
272 KB
Volume
296
Category
Article
ISSN
0003-2697

No coin nor oath required. For personal study only.

✦ Synopsis


Plasminogen activator inhibitor type-1 (PAI-1) is bound to vitronectin (VN) in plasma and in the extracellular matrix. We previously employed a domainswapping approach to show that the high-affinity binding site for PAI-1 in VN is contained within residues 12-30 in the amino-terminal somatomedin B (SMB) domain. In this study, we attempt to further delineate the location of this site by employing a novel approach that is based on the use of monoclonal antibodies (Mabs) together with site-directed mutagenesis. Six separate Mabs were identified that bound to the SMB domain and competed with PAI-1 for binding to VN. The relative affinity of each of the Mabs, and of PAI-1 itself, for binding to individual variants of SMB (prepared by alanine scanning mutagenesis), was then determined and compared in competitive binding experiments. Three separate, partially overlapping Mab epitopes within SMB were defined by these studies, and the PAI-1 binding site was localized to the region between residues 24 and 37. When considered together with the domain swapping data, these studies suggest that the PAI-1 binding site is contained within a common seven-residue region (i.e., residues 24 -30) in the SMB domain.


📜 SIMILAR VOLUMES


Plasminogen activator inhibitor-1 regula
✍ Gary Deng; Scott A. Curriden; Geng Hu; Ralf-Peter Czekay; David J. Loskutoff 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 247 KB

## Abstract Plasminogen activator inhibitor‐1 (PAI‐1) binds to the somatomedin B (SMB) domain of vitronectin. It inhibits the adhesion of U937 cells to vitronectin by competing with the urokinase receptor (uPAR; CD87) on these cells for binding to the same domain. Although the inhibitor also blocks

CE-LIF method for the separation of anth
✍ Gillian Whitaker; Amy Lillquist; Stephanie A. Pasas; Robert O'Connor; Fiona Rega 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 399 KB 👁 2 views

## Abstract Anthracyclines are chemotherapeutic drugs that are widely used in the treatment of cancers such as lung and ovarian cancers. The simultaneous determination of the anthracyclines, daunorubicin, doxorubicin and epirubicin, was achieved using CE coupled to LIF, with an excitation and emiss

NMR chemical shift mapping of the bindin
✍ Jikui Song; John L. Markley 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB

## Abstract The substrate‐like inhibition of serine proteinases by avian ovomucoid domains has provided an excellent model for protein inhibitor‐proteinase interactions of the standard type. ^1^H,^15^N and ^13^C NMR studies have been undertaken on complexes formed between turkey ovomucoid third dom

Basic region of residues 228–231 of prot
✍ Pablo Sobrado; Ana Jedlicki; Victor H. Bustos; Catherine C. Allende; Jorge E. Al 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

Protein kinase CK1, also known as casein kinase 1, participates in the phosphorylation of b-catenin, which regulates the functioning of the Wnt signaling cascade involved in embryogenesis and carcinogenesis. b-catenin phosphorylation occurs in a multiprotein complex assembled on the scaffold protein